NVSEF - MorphoSys climbs after late-stage data for blood cancer therapy
2023-12-11 13:57:54 ET
More on MorphoSys
- MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis
- MorphoSys: Buying Constellation Was A Desperate Measure
- MorphoSys: Still Positive Moving Into Pelabresib Data (Maintaining Buy Rating)
- MorphoSys stock tumbles 24% post-market amid Phase 3 data (update)
- I-Mab gains FDA breakthrough tag for kidney disease therapy
For further details see:
MorphoSys climbs after late-stage data for blood cancer therapy